ArticleGland surgery2026
Development and internal validation of a nomogram for predicting the initial response to radioactive iodine therapy in differentiated thyroid cancer with concurrent Hashimoto's thyroiditis.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Differentiated thyroid cancer (DTC) frequently coexists with Hashimoto's thyroiditis (HT), and HT may influence the response to radioactive iodine (RAI) therapy. This study aims to establish and validate a clinical predictive model for the response to initial RAI therapy in patients with DTC complicated by HT, thereby providing a personalized tool for optimizing clinical decision-making. Methods: A total of 461 patients with DTC and HT were included in the study. Variable selection was conducted using least absolute shrinkage and selection operator (LASSO) regression, followed by the construction of a predictive nomogram based on multivariable binary logistic regression. Model performance was evaluated through receiver operating characteristic (ROC) curve analysis, calibration curve analysis, and decision curve analysis (DCA). Results: Among the 461 patients, 235 achieved an excellent response (ER), while 226 experienced a non-ER (NER). Utilizing five predictors identified by LASSO-N stage, tumor multifocality, lymph node metastasis rate, stimulated thyroglobulin (sTg), and thyroglobulin antibody (TgAb)-a binary logistic regression model and corresponding nomogram were developed. The model demonstrated an area under the ROC curve (AUC) of 0.864 in the training set and 0.882 in the validation set for predicting NER. Moreover, calibration curve analysis and DCA indicated acceptable agreement between predicted and observed outcomes, as well as potential clinical net benefit across a range of threshold probabilities, suggesting that the model may be useful for individualized risk stratification. Conclusions: This study successfully developed and internally validated a clinical prediction model for assessing the response to initial RAI therapy in patients with DTC complicated by HT. The model may serve as a reliable reference for personalized clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.